Market Access Strategy
From strategic commercial planning, through evidence generation, and on to commercialisation support and faciltation, PPi HC offers comprehensive Market Access support. We develop market access strategies and tactical plans for healthcare products and related healthcare services.
Market access means many things to many people. When PPi HC refers to Market Access, we are usually referring to one or more of four basic elements:
- Developing and communicating the "value" of your product to the range of customers who influence uptake. -Considering the implications your product may have on the wider healthcare market
- Understanding the impact the changing healthcare market will have on your product
- Preparing a positive healthcare environment which supports uptake of your product
Strategically, market access can be about packaging data in the right way, for the right customer at the right time. In a changing payer landscape, aligning your product with a moving target is challenging and only by understanding the needs of all stakeholders involved in the adoption, positioning and funding of your product will you be able to develop messages that improve its chances of success.
Development of Market Access Strategies
We help healthcare innovators to optimize the peak sales for their medicinal products, medical devices and methods of treatment. To secure the best pricing opportunities, we tailor the most relevant access pathways and develop scenarios to explore the relevant market access options at both regional and country level. We also explore market access timelines in regard to the evaluation of contracts and supply models, such as managed entry agreements.
Market Access Planning
We support clinical development, the testing of value messages and the launch and marketing of healthcare technologies. Our consulting services are based on data from our expertise, from primary research (e.g. interviewing appropriate level stakeholders from our network, payers and those effecting purchasing and enlistment, or external opinion leaders for diseases of interest) and from the secondary data (e.g. public or private access country level databases).
Services
TESTIMONIALS
“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”
Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.
“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”
Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma
“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
